Safety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With Hypogonadism
brief summary
The goal of this Phase 3 clinical trial is to evaluate the safety, efficacy, and usability of a weekly subcutaneous testosterone cypionate auto-injector in adult males with hypogonadism. The main questions it aims to answer are: * Does weekly testosterone cypionate administered using an auto-injector maintain testosterone levels within the normal range in adult males with hypogonadism? * What side effects and safety outcomes occur during treatment with testosterone cypionate auto-injector? * Is the auto-injector easy for participants to use and self-administer? All participants will receive testosterone cypionate administered subcutaneously once weekly through an auto-injector. Treatment will begin at a 75 mg weekly dose, with dose adjustments to 50 mg or 100 mg based on testosterone levels measured during the study. Participants will: * Receive weekly testosterone cypionate injections using an auto-injector for up to 52 weeks. * Attend regular clinic visits for physical examinations, laboratory tests, blood pressure monitoring, and safety assessments. * Provide blood samples to measure testosterone and other hormone levels and evaluate pharmacokinetics. * Complete questionnaires related to symptoms, quality of life, and ease of use of the auto-injector. * Record self-administration and treatment compliance in a study diary. This study will enroll adult males aged 18 to 75 years with hypogonadism and low testosterone concentrations to evaluate treatment through Week 24, with continued safety follow-up through Week 52.
detailed description
Hypogonadism in adult males is characterized by inadequate testosterone production and may be associated with reduced energy, decreased libido, diminished muscle mass and strength, impaired physical function, and other clinical symptoms. Testosterone replacement therapy is commonly used to restore serum testosterone concentrations to the normal physiological range and improve symptoms associated with testosterone deficiency.
This Phase 3, multicenter, single-arm, multiple-dose study is designed to evaluate the long-term efficacy, safety, pharmacokinetic profile, and usability of testosterone cypionate administered subcutaneously via a prefilled weekly auto-injector in adult males with hypogonadism. The study seeks to characterize the ability of the investigational product to achieve and maintain serum testosterone concentrations within the target eugonadal range during chronic administration.
Participants will initiate treatment with a weekly subcutaneous dose of testosterone cypionate administered using the auto-injector. Dose adjustments may be implemented during the study based on serum testosterone concentrations to optimize therapeutic exposure. Pharmacokinetic assessments will be performed to characterize testosterone exposure following repeated dosing and to evaluate maintenance of testosterone concentrations over time.
In addition to evaluating testosterone concentrations, the study will assess the long-term safety and tolerability of weekly subcutaneous testosterone cypionate. Safety evaluations will include monitoring of adverse events, clinical laboratory parameters, vital signs, physical examinations, and other assessments routinely used to evaluate testosterone replacement therapy.
The study will also evaluate participant experience with the auto-injector, including ease of use and successful self-administration. Information obtained from this study is intended to support the clinical evaluation of a convenient, once-weekly subcutaneous testosterone replacement option for adult males with hypogonadism.
This study includes a treatment period and an extension phase to provide additional long-term safety and efficacy data following repeated administration of testosterone cypionate using the auto-injector device.
official title
A Single-Blind, Single-Arm, Multiple-Dose Study Evaluating the Safety and Efficacy of Testosterone Cypionate Administered Subcutaneously Via a Weekly Auto-Injector in Adult Males With Hypogonadism Through Week 24